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Summary. Synthetic biology enables us to create genes virtually at will. Ensuring that multiple genes are16
efficiently co-expressed within the same cell – to assemble multimeric complexes, to transfer biochemical17
pathways, to transfer ‘traits’, is more problematic. Viruses such as picornaviruses accomplish exactly this18
task: they generate multiple, different, proteins from a single open reading frame. The study of how foot-19
and-mouth disease virus (FMDV) controls it’s protein biogenesis lead to the discovery of a short20
oligopeptide sequence, ‘2A’, that is able to mediate a co-translational ‘cleavage’ between proteins. 2A21
and ‘2A-like’ sequences (from other viruses and cellular sequences) can be used to concatenate multiple22
gene sequences into a single gene, ensuring their co-expression within the same cell. These sequences23
are now being used in the treatment of cancer, in the production of pluripotent stem cells, to create24
transgenic plants and animals amongst a host of other biotechnological and biomedical applications.25
26
27
Keywords. 2A oligopeptide, co-expression, gene therapy, induced pluripotent stem cells, transgenic28
plants, transgenic animals.29
30
31
Protein Co-Expression: What’s The Problem? The advances in polymerase chain reaction (PCR)32
technology alongside those in synthetic biology have transformed our capabilities in the design and33
creation of new gene structural / regulatory sequences. This in itself, however, is not enough. In the early34
days of human gene therapy or the production of transgenic animals or plants, only single transgenes35
could be used successfully - a prime example being the first human gene therapy: four year old Ashanti36
DeSilva, where a lesion in a single gene (adenosine deaminase - causing severe combined immune37
deficiency) was treated with a functional copy of the gene. However, for gene therapy of certain human38
genetic disorders, the production of high-value therapeutic proteins, or, the introduction of ‘traits’ into39
animals or plants via transgenesis, multiple different genes must be co-expressed within the same cell.40
Co-expression of multiple proteins in bacterial cells can be solved in a relatively straightforward41
manner. The initiation of translation in bacteria occurs at short ribosome binding (Shine-Dalgarno)42
sequences proximal to the initiating AUG codon. Such sequences are internal to the messenger RNA43
(mRNA): this method of initiation is fundamentally different in eukaryotes where translation initiation44
factors must bind to a cap structure at the 5’ end of an mRNA. In eukaryotes, once the stop codon has45
2been reached at the end of the open reading frame (ORF), translation terminates and must normally re-1
initiate via a 5’ mRNA cap structure. In bacteria, genes requiring co-ordinated co-expression can simply be2
concatenated using short intergenic regions encoding ribosome binding sites – an operon. Here, multiple3
genes (cistrons) are transcribed into a polycistronic mRNA where each gene is translated independently4
by internal initiation of translation at the multiple (intergenic) ribosome binding sites. Due to the5
completely different method of initiation of translation, this strategy of co-expression cannot be used in6
eukaryotes.7
Whilst transfection of cells with a mixture of different plasmid DNAs (each encoding a different8
transgene) may produce effective co-expression taken across the population of cells, it will only produce a9
small proportion of individual cells co-expressing all of the products – albeit with a range of comparative10
levels of expression of each transgene. Naturally, the transcription of these individual, dispersed, genes11
must be controlled in a co-ordinated manner. Long-term stable expression requires integration of the12
different plasmid DNAs into the genome: without sophisticated ‘targeting’ strategies, the integration of13
individual transgenes occurs at sites dispersed – at random - throughout the genome. This leads to14
genetic instability in the longer-term, and the consequential loss of the desired phenotype due to the loss15
of expression of one, or more, of the transgenes.16
Why is the ability to co-express multiple proteins within the same cell so important? An excellent17
example is the production of antibodies: both the heavy and light chains need to co-expressed within the18
same cell so that the different chains can be assembled into a functional complex as they are exported19
from the cell. Expressing the heavy chain in one cell and the light chain in another cell would not produce20
a functional product. This principle applies across the board: production of therapeutic proteins (protein21
complexes), gene therapy and, for example, the introduction of biochemical pathways into transgenic22
organisms (e.g. ‘Golden Rice’).23
In attempts to improve the efficiency of co-ordinated co-expression, various strategies have been24
employed: placing multiple genes on the same plasmid DNA, using multiple divergent or tandem25
promoters – but none have proved to be a significant advance. One solution to this problem is to26
concatenate sequences encoding proteins via linkers (which comprise host-cell proteinase cleavage sites)27
into a single ORF. This strategy has the disadvantage of problems which may arise from tissue/species28
specificity of proteinase expression, and, that ‘processing’ of the fusion protein is post-, and not co-,29
translational. The latter aspect precludes strategies involving the co-expression of cellular proteins which30
are either secreted from the cell, located within the lumen/membranes of cytoplasmic vesicular31
structures (excluding mitochondria), or, are plasma membrane proteins – some 39% of all mammalian32
proteins. Viruses, such as FMDV, encode proteinase domains within their polyproteins which ‘process’33
precursors into mature products. A common problem here is that although these virus-encoded34
proteinases are specific for the virus polyprotein, they are cytotoxic in that they have evolved to also35
cleave certain key host-cell proteins to manipulate host-cell metabolism or modify macromolecular36
structures to promote virus replication – not a desirable property for a co-expression system. Certain37
virus-encoded proteins have been used to great effect in cleaving expressed, purified, fusion proteins in38
vitro (the plant virus Tobacco Etch Virus proteinase, for example), but the cytotoxic ‘off-target’ cleavage39
of host-cell proteins in vivo remains a problem. Re-iterative rounds of transgenesis combined with40
selection has been used successfully in, for example, the production of plant transgenes - but this41
strategy simply cannot be used in many biomedical applications where the window to treat the disease in42
question may be limited.43
Protein Co-Expression: What’s The Solution? Fortunately for biotechnologists, it turns out that the co-44
expression problem has already been the subject of highly intensive experimentation – indeed, billions45
3upon billions of experiments: very elegant solutions to the co-expression problem have been developed -1
by viruses. The genome structure of picornaviruses, such as FMDV, have the same overall architecture as2
cellular mRNAs: a 5’ non-coding region (5’NCR), a single ORF (in picornaviruses encoding a ‘polyprotein’),3
a 3’ non-coding region and a poly-A tail (Figure 1). Picornaviruses co-express capsid proteins, proteins4
involved in altering host-cell macromolecular structures and metabolism, plus proteins to replicate the5
virus RNA genome – all from a single ORF. In most cases this is accomplished by the virus encoding its own6
proteinases (domains of the polyprotein) which serve to cleave the polyprotein substrate at specific sites7
to produce the individual ‘processing’ products. Parenthetically, these proteinases also serve to degrade8
specific host-cell proteins to promote virus replication (reviewed in [1]). However, relatively recently an9
alternative method of controlling protein biogenesis was discovered – ribosome ‘skipping’ – which has10
lead to a revolution in protein co-expression technology.11
The N-terminal protein of the FMDV polyprotein is a proteinase (Lpro), which cleaves at its own C-12
terminus. Lpro also cleaves the cellular translation initiation factor eIF4G – ‘shutting off’ host-cell cap-13
dependent mRNA translation. The FMDV genome is, however, translated from an internal ribosome entry14
sequence (IRES; Figure 1, Panel A) in a cap-independent mechanism. In this manner the virus sequesters15
the resources of the cell for its own replication. Indeed, picornavirus IRESes provided an early method of16
creating a bicistronic mRNA such that 2 proteins could be co-expressed from a single mRNA (Figure 1,17
Panel B; discussed in [1]). The first ORF is translated in a cap-dependent manner, the second ORF in a cap-18
independent manner - driven by the IRES. The draw-back of this system is that the second ORF is19
translated only to some 10% of the first ORF: this ‘polarity’ effect being exacerbated when one uses20
multiple IRESes to express more than 2 genes.21
A co-translational ‘cleavage’ of the FMDV polyprotein occurs at the C-terminus of 2A (only 18aa22
long; Figure 1, Panel A). Analyses of recombinant FMDV polyproteins indicated the FMDV 2A oligopeptide23
appeared to mediate this cleavage without the involvement of other FMDV proteins. This hypothesis was24
subsequently confirmed by inserting the FMDV 2A sequence (together with the N-terminal proline of25
protein 2B – collectively referred-to as ‘2A’) into artificial polyprotein systems. These systems comprised26
two ‘reporter’ proteins flanking FMDV 2A: a single ORF was created by removing the stop codon of the27
protein upstream of 2A (Figure 1, Panel C). Analyses of these types of construct in cell-free translation28
systems and transfected cells showed;29
 the FMDV 2A oligopeptide sequence mediated a highly efficient ‘cleavage’ (>90%)30
 2A ‘cleaved’ at it’s own C-terminus – just like in the FMDV polyprotein31
 2A-mediated ‘cleavage’ was co-, and not post-, translational32
Importantly, these artificial polyprotein systems, designed for analyses of the mechanism of the 2A-33
mediated ‘cleavage’, provided the first demonstration that 2A could be used to co-express multiple34
proteins [2-4].35
The 2A Co-Expression System. Using this approach of artificial self-processing polyprotein systems in36
plant, yeast, insect and mammalian cells, the indication was that 2A could work in all eukaryotic37
expression systems and (unlike IRESes) worked highly efficiently in all cell types. ‘2A-like’ sequences were38
identified from other viruses and cellular genomes and a number proved to match, or exceed, the39
‘cleavage’ efficiency of the FMDV 2A sequence [5,6]. Our analyses of the mechanism showed that 2A was40
neither a substrate for a host-cell proteinase, nor a proteolytic element itself, but mediated a ribosomal41
‘skipping’ event in which the synthesis of a specific peptide bond was ‘skipped’: translation terminated at42
the C-terminus of 2A, but could re-initiate at the N-terminal proline of the downstream protein. The43
4‘cleavage’ products were, in fact, generated as discrete translation products. Our model of 2A-mediated,1
co-translational, ‘cleavage’ proposes the nascent 2A oligopeptide interacts with the ribosome exit tunnel.2
This interaction leads to a modification and restriction of the conformational space of the peptidyl-tRNA3
within the peptidyl-transferase centre of the ribosome - ‘jamming’ the process of polypeptide elongation.4
This jam is overcome by release (termination) factors eRF1 and eRF3 releasing the nascent protein, then5
the ribosome may re-commence elongation of the downstream protein: the individual products do not6
arise from a substrate undergoing proteolysis, but are actually synthesised as discrete translation7
products (reviewed in [2]).8
This mechanism imparts no ‘polarity’ on the system – more than 2 proteins can be concatenated9
without affecting the ‘cleavage’ at other 2A linker sequences. The 2A system does however, have10
drawbacks: (i) the system does not work in prokaryotic cells, (ii) the 2A (or 2A-like) oligopeptide sequence11
remains as a C-terminal extension (some 18-25aa) of the upstream protein and (iii) the downstream12
protein must have an N-terminal proline residue. Although an N-terminal proline confers a long half-life13
upon a protein, it does preclude many N-terminal post-translational modifications that may be essential14
for activity. If this is the case, such a protein should be placed first in the chain of concatenated15
sequences.16
For the reasons outlined above, the 2A system is not ideal - but it is the best, and has proven to17
be an extremely useful tool in biotechnology and biomedicine. For the first time multiple proteins could18
be co-expressed – in equal stoichiometry – from a single promoter. Our translational model of 2A-19
mediated ‘cleavage’ predicted that 2A modified the translational apparatus – 2A worked within the20
ribosome. To test this model we incorporated co-translational signal sequences immediately downstream21
of 2A. If the model was correct, these signal sequences would be recognised as nascent N-terminal22
features by signal recognition particle and target the second protein to the exocytic pathway [7]. This23
indeed proved to be the case, adding more support for our model - but also imparting a new dimension to24
the utility of the system: one could not only co-express multiple proteins, but potentially target individual25
components to different sub-cellular sites. It should be noted, however, that the 2A-mediated cleavage26
may be inhibited in the case of some proteins targeted to the exocytic pathway [8].27
Although individual cells express these self-processing polyproteins at different levels, the key28
point is that within a cell, each component of the polyprotein is expressed at the same levels. This is29
shown in figure 2 (panel A), showing images of cells transfected with a plasmid encoding green30
fluorescent protein, linked via Thosea asigna virus 2A (TaV2A), to cherry fluorescent protein (cherryFP).31
The [GFP-TaV2A-CherryFP] ORF is translated into [GFP-TaV2A] and CherryFP – no uncleaved [GFP-TaV2A-32
CherryFP] is detected (data not shown). Fluorescence image analyses (Figure 2, panel A) show that these33
proteins are expressed to the same level within any given cell.34
2A was first characterised in FMDV, although it was apparent that other picornaviruses encoded35
‘ribosome skipping’ 2As, and that this method of controlling protein biogenesis was also used by a wide36
range of other RNA viruses: indeed, some of these viruses encode multiple 2A-like sequences [5]. A37
number of these virus ‘2A-like’ sequences have been used in biomedicine and biotechnology (Table 1),38
but a wider range of other, highly efficient, 2As could be used (Table 2). Some researchers seeking to use39
2A have expressed concern with regards the public acceptance of products comprising sequences derived40
from viruses, but we have identified other efficient 2A-like sequences from cellular genes which could be41
used to replace virus sequences [6, unpublished observations] (Table3).42
Biotechnological Applications. Since the early observations on the properties of the 2A oligopeptide43
sequence were published in virology journals, many early uses involved the creation of recombinant virus44
genomes (e.g. influenza virus, poliovirus, plant potex- and comoviruses). For cellular systems, early45
5applications were relatively simple: (i) to link the sequences encoding the two different components of a1
heterodimer (e.g. high-value therapeutic proteins such as interleukin 12, monoclonal antibodies), (ii) to2
link two different reporter proteins to provide proof-of-principle for co-expression in various target cell-3
types/organisms, or, (iii) to monitor the expression of a (trans)gene by linking it to a marker protein(s)4
(e.g. GFP, luciferase). Using the latter approach, the site of expression of a therapeutic transgene within5
an organism could be studied by histology or whole-body imaging.6
Once the utility of the system became more apparent, more ambitious constructs were7
assembled – notably the co-expression of all of the components of an active T-cell receptor complex (68
different proteins – see below). Such a dramatic demonstration of the utility of 2A helped raise the9
‘profile’ and the potential of the system. Over time data accumulated from a wider range of proteins and10
eukaryotic cell-types showing that, indeed, the 2A co-expression system worked in all eukaryotic cell-11
types tested: yeast, fungal, plant, insect and mammalian. An impression of the utility of the this co-12
expression system can be gained by viewing the range and huge number of publications citing the use of13
2A (http://www.st-andrews. ac.uk/ryanlab/page10.htm).14
15
Transgenic Organisms. Breeders classically ‘stack’ genes by a program of re-iterative crossing between16
parents each with a desired trait, then identifying offspring expressing both traits. In some cases,17
however, the generation time of the target species places a major constraint on this process rendering it18
impractical. Gene stacking by genetic engineering is a term used in the plant sciences, but here we will19
use the term, in the sense of a general procedure, for the production of both plant and animal genetically-20
modified organisms (GMOs). In many publications researchers have chosen to provide a proof-of-principle21
by co-expression of multiple fluorescent proteins, since these are encoded by relatively small genes, the22
translation products are readily detected by microscopy and the efficiency of co-expression23
demonstrated.24
(i) Transgenic Plants. The early analyses of the mechanism of 2A-mediated ‘cleavage’ showed 2A was25
equally active in animal- (rabbit reticulocyte lysates) and plant-based (wheat-germ extracts) cell-free26
translation systems. It was also shown that (i) 2A could be used to co-express proteins in transgenic27
tobacco cells and (ii) 2A could be used to manipulate plant virus genomes. Indeed, research was28
conducted to use (non-GMO) plants as production platforms - programmed with recombinant plant29
viruses encoding 2A to co-express high-value proteins, either as free proteins, or, on the surface of plant30
virus particles. Since then, 2A has been used to create a wide range of transgenic plants; drought-resistant31
crops, crops with improved nutritional values, the production of a new generation of golden rice, to32
engineer crops to produce ‘nutraceuticals’, to engineer plant metabolic pathways and, more recently, to33
stack the genes for glyphosate-resistance with BT-toxins (the World’s two most common transgenes) in34
the form of a self-processing polyprotein [9-17].35
(ii) Transgenic Animals. 2A has been used successfully in the production of a wide range of transgenic36
animals; mice [18-27], fish [28, 29], rats [30], pigs [31, 32], birds [33], amphibians [34], insects [35] and37
sheep [36]. Again, many publications describing the generation of GMOs to provide a proof-of-principle38
(using reporter genes), to create transgenic animals as research tools, for developmental studies, for39
histological studies, as models of human diseases, to produce animal models of human disease, develop40
therapies etc. – but, to date, there are no reports of the use of 2A in the introduction of traits designed to41
increase nutritional values, enhance productivity/disease resistance or to add value to the animal product42
– the technology remains largely as a research tool.43
44
6Biomedical Applications. Politics, particularly in Europe, has substantially delayed the use of GMOs in1
agriculture. In the field of biomedicine, however, the story could not be more different. Here, 2A has2
been used not only as an effective research tool to monitor the expression of therapeutic transgenes by3
linking them, via 2A, to marker proteins [37], but also as an integral part of effective therapies in the4
clinic. Literally hundreds of papers have been published citing the use of 2A in a broad range of5
biomedical applications. It is beyond the scope of this review to do justice to all of the work, but the work6
outlined in the sections below describes some of the truly astonishing recent advances in molecular7
medicine: astonishing not only in the scientific vision that underpins these advances, but also the rapidity8
in which these developments have reached patients.9
10
(i) ‘Transferable’ Immune Responses (TIRs). Herd (or community) immunity is present when the11
vaccination of a portion of a population is sufficient to provide an effective measure of protection for12
susceptible individuals: chains of infection are likely to be broken and the basic reproduction number (Ro)13
of the infectious agent falls below 1. Over the past few years, however, we have witnessed the14
development of technologies which will bring about another form of immunity arising not from the15
immune repertoire of the individual in question, but from the repertoire of the ‘herd’: ‘transferable16
immune responses’. Here, a susceptible individual could benefit from the immune response of another:17
not indirectly, by breaking a chain of transmission, but in a direct manner by the transfer of genetic18
information – conferring an immune trait from another individual in the population.19
(a) Adoptive Cell Transfer (Engineered T-cells). In the 1980s it was shown that cancers regressed20
following treatment with autologous tumour-infiltrating lymphocytes. Tumour-associated antigens may21
be recognised by T-cell receptors (TCRs), composed of alpha and beta chains. Once reactive TCRs were22
identified and purified, it was possible to clone the genes encoding these chains, chains that were critical23
in the T-cells recognising and killing the cancerous cells. This lead to a new form of treating cancer:24
adoptive cell transfer (ACT). In essence, peripheral blood lymphocytes (PBLs) are isolated from the25
patient, transduced with genes encoding the desired TCR which targets the cancer cells (ex vivo gene26
therapy), and the (autologous) genetically-modified cells introduced back into the patient. The cytotoxic27
T-cells attack and destroy the cancer cells. Initially, genes encoding the alpha and beta chains were28
introduced as individual genes, or, linked by an IRES to improve co-expression. Again, the use of 2A to co-29
express these chains proved to be a substantial advance in their co-expression and assembly into a30
functional complex [18].31
This strategy showed that the T-cell repertoire of an individual could be modified or expanded by32
harnessing – via gene transfer – the result of a successful immune response mounted by another33
individual. Indeed, this form of ACT using 2A to co-express TCR alpha and beta chains has been used to34
treat a range of cancers: metastatic melanoma, synovial cell sarcomas, colorectal cancer and renal cell35
carcinomas, but the list is expanding rapidly [38-45]. Naturally there are problems associated with this36
type of therapy, such as (i) targeting of normal tissues (autoreactivity) expressing the cognate antigen and37
the formation of ‘chimeric’ TCRs in which an exogenous (gene transferred) receptor chain associates with38
an endogenous chain, (ii) loss of potency during T-cell manipulation before transduction, and (iii) the39
relatively shorter life of peripheral blood T-cells: problems which will be overcome. ACT represents a very40
exciting development in the field of cancer therapy.41
(b) Engineered B-cells. ‘Passive’ immunity against pathogens, or toxins, may be achieved simply42
by the transfer of antibodies (animal or human in origin) to the patient. Like TCRs, the production of43
functional antibodies requires co-expression (heavy and light chains) within the same cell. The use of 2A44
to express the two different antibody chains was carefully optimised by Cell Genesys Inc. [46, 47]. The45
7heavy chain (plus it’s signal sequence) was linked to the light chain (plus it’s signal sequence) via 2A within1
a recombinant adeno-associated virus vector (rAAV). Therapeutic levels of antibodies were secreted from2
rAAV transduced mouse cells. Incorporation of a furin proteinase cleavage site between the heavy chain3
and 2A resulted in the C-terminal extension of 2A being ‘trimmed’ away by the cellular furin – a4
proteinase located mainly in the Golgi apparatus.5
This approach of heavy/light chain co-expression was transformed into a new therapeutic6
strategy by the production of recombinant B-cells. However, were mature B-cells to be transduced with7
such a [heavy chain-2A-light chain] type of construct, the same problem of mixing of the endogenous and8
exogenous antibody chains would be encountered, as outlined above for the T-cell receptor alpha and9
beta chains. The solution was to transduce (naive) human hematopoietic stem/progenitor cells (HSPCs),10
then to drive differentiation (in vitro) of the transduced HSPCs into mature B-cells: the most potent11
antibody-producing cells [48, 49]. This approach was adopted to produce anti-HIV antibodies, but the12
principle of an immune response, transferable from one individual to another, was demonstrated.13
Subsequently this approach was extended to T-cells by the transduction of HSPCs with disease-specific14
TCRs, leading to the generation of long-lasting and functional cytotoxic T-cells, solving the chain-mixing15
and T-cell longevity problems [50].16
17
(ii) Pluripotent Stem Cells. One major area of regenerative medicine is the use of stem cells to regenerate18
damaged tissues. The main sources of autologous stem cells in adults are the bone marrow, adipose19
tissue and blood. The problems associated with isolation of stem cells from such tissues could be20
overcome by producing stem cells from differentiated tissue, rather than their direct isolation from the21
body. Such a technology would also circumvent the ethical issues surrounding the isolation and use of22
embryonic stem cells. Combinations of genes known to be particularly important in embryonic stem cells23
were transduced into (differentiated) mouse fibroblasts. In this manner, four genes were identified (Oct-24
3/4, SOX2, c-Myc, and Klf4) which, when co-expressed in the same cell, lead to the production of induced25
pluripotent stem cells (iPSCs): the differentiation into a fibroblast had been reversed. Initially, these26
individual genes were co-expressed using multiple lentivirus vectors, but the laboratory of Shinya27
Yamanaka at Kyoto University chose to link these genes, via 2As, to create a single, self-processing,28
polyprotein [51]. This strategy ensured the co-expression of the multiple proteins within the same cell -29
vital for iPSC production. The use of 2A for co-expression has been adopted by many laboratories to30
produce iPSCs [52-74]. The technologies developed to produce iPSCs has advanced with astonishing31
rapidity – a reflection of the huge potential in the field of regenerative medicine. Patient-specific iPSCs32
can now be produced ex vivo for the administration of cells to treat disease, but one can conceive of33
transduction of cells in vivo – a gene therapy approach to tissue regeneration.34
35
Future Perspective. Basic research into how FMDV generates multiple proteins from a single open reading36
frame led to the discovery of how the 2A oligopeptide mediates a co-translational ‘cleavage’: a discovery37
that has facilitated a bewildering array of biotechnological and biomedical applications.38
In some ways, however, the true potential of this system remains to be exploited: to date only a39
few publications cite the use of 2A in engineering or the transfer of biochemical pathways. Here one40
thinks of ‘dual use’ crops (e.g. eat one part, ferment another for biofuels), improving the nutritional41
properties of crops, improving abiotic and abiotic/biotic stress resistance (drought/salinity/pests/viruses),42
creation of crops able to fix nitrogen, and the genetic modification of algae/fungi/yeasts for biofuel43
production. In animal biotechnology one naturally thinks of disease resistance (multivalent vaccines, anti-44
microbial peptides, modification of the innate immune system etc.), the production of high-value or45
8therapeutic proteins (e.g. the ill-fated PPL Therapeutics) and productivity (e.g. AquAdvantage salmon). In1
the arena of human health, 2A conferring the ability to perform more complex transgenesis has opened2
the door to new strategies of immuno-therapy: not only of cancer, but potentially of much wider3
significance: methamphetamine abuse for example [75], but also monoclonal antibodies directed against4
other small molecules such as the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-5
butanone [76].6
A Sensor of Translational Stress? A further potential future use of 2A arises from our model of the7
mechanism of 2A-mediated cleavage. The model invokes a key step in the re-initiation of the translation8
of sequences downstream of 2A, mediated by eukaryotic elongation factor 2 (eEF2) [1-4, 77]. The activity9
of eEF2 is regulated by eEF2 kinase. The activity of eEF2 kinase is also regulated by phosphorylation, but in10
this case by a series of signalling pathways related to different forms of cellular stress (hypoxia,11
temperature, amino-acid starvation, alcohol etc.), such that when cells become stressed both the12
initiation and the elongation phases of translation are down-regulated.13
The hypothesis we are currently testing is that as cells become stressed (such as FMDV infection),14
eEF2 becomes increasingly phosphorylated, leading to a progressive reduction in the rate of polypeptide15
elongation. Re-initiation of translation of the downstream sequences would be very sensitive to such a16
reduction: termination at the 2A site would be progressively increased and re-initiation progressively17
decreased. The net effect being an increase in the molar ratio of upstream : downstream products as a18
response to increasing cellular stress. In the case of FMDV infection, this would result in the synthesis of a19
higher ratio of capsid proteins : replication proteins as the infectious cycle progresses. At the latter stages20
of infection, what remains of the cell’s resources (amino-acyl tRNAs) would be progressively targeted to21
the synthesis of capsid, and not replication, proteins – increasing the yield of virus particles. If this indeed22
proves to be the case, 2A could be used not just to co-express proteins – but to be used as a ‘sensor’ of23
translational stress. Since 2A works in all eukaryotic systems tested to date, such a sensor could be used24
for both plant and animal biotechnologies.25
Dual Protein Targeting. Recently the complete genome sequence of the purple sea urchin26
(Strongylocentrotus purpuratus) was published [78]. Our bioinformatic analyses of the genome showed27
2A-like sequences were detected in two major types of gene: non-LTR retrotransposons and28
‘CATERPILLER’ proteins of the innate immune system. We were perplexed, however, in that these latter29
genes 2A-like sequences occurred at the N-terminus of the ORF. What could be the purpose of a self-30
cleaving sequence at the N-terminus? We have recently shown that these 2A-like sequences are active in31
mediating ‘cleavage’ (to various degrees) – but that they may also function as signal sequences, targeting32
the (downstream, ‘uncleaved’) protein to the exocytic pathway. In the case of one 2A-like sequence33
(STR6-2A; Table 3), the wild-type sequence shows high ‘cleavage’ activity: if the signal sequence ‘cleaves’34
itself from the downstream protein then the protein localises to the cytoplasm. The 2A-like signal35
sequence ‘cleaves’ itself away from the downstream protein within the ribosome such that the protein36
emerges from the ribosome without a signal at its N-terminus. If the 2A-like signal sequence does not37
cleave, however, the signal remains attached, is recognised by signal recognition particle, and the entire38
protein is targeted to the exocytic pathway. To demonstrate this effect, we fused such a 2A-like signal39
sequence to CherryFP. The wild-type (signal) sequence (STR6-2Awt; Table 3) cleaved itself from CherryFP40
(data not shown), such that CherryFP – lacking any signal sequence - was localised to the cytoplasm41
(Figure 2, Panel B). A site-directed mutant form (STR6-2Amut; Table 3) is ‘cleavage’ inactive (data not42
shown): in this case the 2A-like signal sequence remains attached to the downstream protein and targets43
the entire protein to the exocytic pathway (Figure 2, Panel B). This represents, therefore, a novel form of44
dual protein targeting.45
9We are currently both characterising natural sequence variants and developing mutants to1
provide a range of sequences which could be used to determine the proportion of the expressed protein2
which partitions between localisation in the cytoplasm and secretion from the cell. A single (trans)gene3
translation product could, therefore, be localised in both the cytoplasm and be secreted from the cell.4
This entirely new property of this class of 2A-like sequences could be of utility in biotechnological and5
biomedical applications.6
7
The biology associated with this oligopeptide sequence has proven to be fascinating and the diverse uses8
to which to 2A has been put is amazing: to paraphrase - ‘never in the field of biotechnology was so much9
owed by so many to so few (amino acids)’.10
11
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Legends to Figures.1
2
Figure 1. The genome structure of FMDV and picornavirus sequences used in co-expression. The overall3
architecture of the picornavirus genome resembles that of a cellular mRNA. The virus RNA cap4
structure comprises an oligopeptide (VPg), rather than the 7meG of mRNAs. The FMDV 5’ non-coding5
region (NCR) comprises an internal ribosome entry sequence (IRES) preceding the single, long, open6
reading frame (ORF; boxed area). The polyprotein comprises the L proteinase (Lpro), the capsid7
proteins domain, 2A and two domains which together comprise the replication proteins. The8
sequence of 2A is shown together with the site of ‘cleavage’ (arrow) and the N-terminal proline of9
protein 2B, immediately downstream of 2A. The short 3’NCR bears a poly-A tail (Panel A). The first10
bicistronic mRNAs utilised the cap-independent mode of translation conferred by the IRES. The first11
ORF is translated in the canonical manner for the 5’ 7meG-cap structure, whilst translation of the12
second ORF is cap-independent driven by the IRES – although only to some 10% of the first ORF13
(Panel B). Gene sequences 1 (stop codon removed) and 2 are concatenated into a single (trans)gene14
via a 2A linker. The translation products are synthesised in an equimolar ratio, although; (i) protein 115
upstream of 2A bears a C-terminal extension of 2A and (ii) protein 2 bears an N-terminal proline16
residue (Panel C).17
18
Figure 2. Use of 2A in protein coexpression and dual protein targeting. Sequences encoding GFP and19
CherryFP were linked via TaV2A into a single ORF. HeLa cells transfected with this construct produced20
the ‘cleavage’ products [GFP-TaV2A] and CherryFP. Image analyses show individual cells expresses21
each product to the same level, although different cells have different expression levels (A). The wild-22
type STR6-2A sequence and a point-mutated (‘cleavage’ inactive) form (STR6-2Amut) were fused to23
the N-terminus of CherryFP. The wild-type sequence is highly active in mediating ‘cleavage’ and,24
therefore, CherryFP emerges from the ribosome lacking any signal sequence: it is localised25
throughout the cytoplasm and diffuses into the nucleus. The mutant, ‘cleavage’ inactive, form26
remains fused to the N-terminus of CherryFP, is recognised by signal recognition particle (SRP) and27
targets CherryFP to the exocytic pathway: transiting through the ER and the characteristic28
perinuclear crescent shape of the Golgi apparatus (B).29
30
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Executive summary
Features of the 2A co-expression system
 Multiple coding sequences are concatenated into a single gene (single open reading frame) via 2A
linker sequences
 Each component is translated as a discrete product
 No theoretical upper limit as to the number of genes which may be co-expressed
 Co- and post-translational protein targeting (signal) sequences may be incorporated within the
polyprotein: proteins may be co-expressed and targeted to different sub-cellular sites
 Complex traits / components of multimeric complexes can be co-expressed from a single
transgene
Drawbacks of the 2A co-expression system
 2A remains as a C-terminal extension of the upstream protein
 Protein downstream of 2A bears an N-terminal proline residue (may preclude certain post-
translational modifications)
Advantages over IRES co-expression
 2A co-expression system works in all tissue-types / eukaryotic organisms
 Smaller size (~50-100bp)
 No ‘polarity’ effect: each translation product synthesised in equimolar quantities
Future perspective
 Substantial expansion of the use of 2A-mediated co-expression in the field of transferable
immune responses (TIRs): to combat cancer, inherited genetic disorders and infectious agents
 Widespread use of 2A in the production of patient-specific induced pluripotent stem cells
 Genetic modification of fungi and yeasts for biotechnology
 Genetic modification of domesticated animals to improve health, increase yields, introduce
complex traits
 ‘Stacking’ transgenes in the genetic modification of crop species: use of 2A in the production of
‘dual-use’ / increased nutritive value / disease resistance / abiotic stress resistance / pesticide
tolerance
 Potential novel use as a sensor of cellular stress
 Use of N-terminal signal sequence 2As for dual protein targeting of an expressed protein:
localisation within the cytoplasm and entry into the exocytic pathway
2
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Table 1. Examples of 2A / 2A-like sequences used in biomedicine and biotechnology.7
Virus Abbreviation 2A / 2A-like sequence References
Picornaviridae
Foot-and-mouth disease virus FMDV -PVKQLLNFDLLKLAGDVESNPG P- 9,11,12,15,18,47,51,62.
Equine rhinitis A virus ERAV -QCTNYALLKLAGDVESNPG P- 18,61,62.
Porcine teschovirus-1 PTV1 -ATNFSLLKQAGDVEENPG P- 28,37,44,61.
Tetraviridae
Thosea asigna virus TaV -EGRGSLLTCGDVESNPG P- 18,22,37,39,61,62.
The –DxExNPG P- motif conserved amongst 2A/2A-like sequences is shown in bold.8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
18
1
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Table 2. Active 2A sequences in viruses.2
Virus Abbreviation 2A Sequence
Positive-stranded RNA viruses
Picornaviruses (primarily mammals)
Theiler’s murine encephalomyelitis virus TMEV -FREFFKAVRGYHADYYKQRLIHDVEMNPG P-
Encephalomyocarditis virus EMCV -VFGLYRIFNAHYAGYFADLLIHDIETNPG P-
Saffold virus SAF-V -FTDFFKAVRDYHASYYKQRLQHDVETNPG P-
Equine rhinitis B virus ERBV-1 -EATLSTILSEGATNFSLLKLAGDVELNPG P-
Ljungan virus LV -YFNIMHSDEMDFAGGKFLNQCGDVETNPG P-
Iflaviruses (insects)
Infectious flacherie virus IFV -PSIGNVARTLTRAEIEDELIRAGIESNPG P-
Ectropis oblique picorna-like virus EoPV-2A1 -PSIGNVARTLTRAEIEDELIRAGIESNPG P-
EoPV-2A2 -TRGGLQRQNIIGGGQRDLTQDGDIESNPG P-
Perina nuda picorna-like virus PnPV-2A1 -GQRTTEQIVTAQGWVPDLTVDGDVESNPG P-
PnPV-2A2 -TRGGLRRQNIIGGGQKDLTQDGDIESNPG P-
Tetraviruses (insects)
Euprosterna elaeasa virus EeV -RRLPESAQLPQGAGRGSLVTCGDVEENPG P-
Providence virus PRV-2A1 -LEMKESNSGYVVGGRGSLLTCGDVESNPG P-
PRV-2A2 -NSDDEEPEYPRGDPIEDLTDDGDIEKNPG P-
PRV-2A3 -TIMGNIMTLAGSGGRGSLLTAGDVEKNPG P-
Dicistroviruses (insects)
Cricket paralysis virus CrPV -LVSSNDECRAFLRKRTQLLMSGDVESNPG P-
Acute bee paralysis virus ABPV -TGFLNKLYHCGSWTDILLLLSGDVETNPG P-
Double-stranded RNA viruses
Rotaviruses (mammalian)
Bovine rotavirus C BoRV-C -GIGNPLIVANSKFQIDRILISGDIELNPG P-
Human rotavirus C HuRV-C -GAGYPLIVANSKFQIDKILISGDIELNPG P-
New Adult diarrhoea virus ADRV-N -FFDSVWVYHLANSSWVRDLTRECIESNPG P-
Cypoviruses (insect)
Bombyx mori cypovirus 1 BmCPV-1 -RTAFDFQQDVFRSNYDLLKLCGDIESNPG P-
Operophtera brumata cypovirus-18 OpbuCPV-18 -IHANDYQMAVFKSNYDLLKLCGDVESNPG P-
Totiviruses (crustaceans)
Infectious myonecrosis virus IMNV-2A1 -WDPTYIEISDCMLPPPDLTSCGDVESNPG P-
IMNV-2A2 -RDVRYIEKPEDKEEHTDILLSGDVESNPG P-
The –DxExNPG P- motif conserved amongst 2A/2A-like sequences is shown in bold.3
4
5
20
1
Table 3. Active 2A cellular sequences.2
Cellular 2A Name 2A sequence
Non-LTR retrotransposons [6]
Trypanosoma spp
T.brucei Ingi -RSLGTCKRAISSIIRTKMLVSGDVEENPG P-
T.cruzi L1Tc -QRYTYRLRAVCDAQRQKLLLSGDIEQNPG P-
Strongylocentrotus purpuratus (purple sea urchin)
STR-32_SP -NSSCVLNIRSTSHLAILLLLSGQVEPNPG P-
STR-51_SP -SRPILYYSNTTASFQLSTLLSGDIEPNPG P-
STR-61_SP -GARIRYYNNSSATFQTILMTCGDVDPNPG P-
STR-69_SP -CRRIAYYSNSDCTFRLELLKSGDIQSNPG P-
STR-197_SP -KHPILYYTNGESSFQIELLSCGDINPNPG P-
Crassostrea gigas (Pacific oyster)
CR1-1_CGi -SRHIVVYNFYLQFFMFLLLLCGDIEVNPG P-
Lottia gigantean (Owl limpet)
CR1-1_LG -TLLNDTFSSILYYCFILIIRSGDIELNPG P-
Aplysia californica (California sea slug)
ingi-1_AC -PGFFLGGQHNPAWLARLLILAGDVEQNPG P-
CATERPILLER proteins (unpublished)
S.purpuratus
STR6-2Awt MDGFCLLYLLLILLMRSGDVETNPG P-
STR6-2Amut MDGFCLLYLLLILLMRSGDVETNAG P-
STR6-2Amut: site of mutation (Pro ї ůĂͿƚŽĐƌĞĂƚĞĂĐůĞĂǀ ĂŐĞŝŶĂĐƟǀ ĞŵƵƚĂŶƚ - underlined3
4
5
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